In addition, the levels of IgG2a Abs were significantly higher in TCL-M2 group than in other 3 groups (P < 0.05).
DNA-topoisomerase-1 abs were significantly decreased in the sera from HOCl mice treated with DPTTS compared with untreated HOCl mice (1.47 A.U. ± 0.09 versus 1.96 A.U. ± 0.1; P < 0.05; Figure 5b).
Most importantly, the levels of IgG Abs were significantly higher in DT-TCL-M2 group than in TCL-DT or TCL-M2 group (P < 0.05), indicating that the highest level of IgG Abs was stimulated in DT-TCL-M2 group among all groups.
The levels of IgG1 Abs were significantly higher in TCL-DT and DT-TCL-M2 groups than in other groups (P < 0.01) and were significantly higher in TCL-DT group than in DT-TCL-M2 group (P < 0.05), but were similar among TCL-M2, TCL-NS, and TCL groups (P > 0.05).
The clinical characteristics of the OPC patients are shown in Table 3. Human papillomavirus type 16 E1, NE2, CE2, E4, E6, E7, and L1-specific Abs were significantly more common among OPC patient sera compared with healthy controls (E1, NE2, CE2, E4, E6, E7, and L1, each P<0.007).
The levels of specific IgG Abs were significantly higher in TCL-DT, TCL-M2, and DT-TCL-M2 groups than in TCL-NS and TCL groups (P < 0.01), but were similar between TCL-DT and TCL-M2 groups or between TCL-NS and TCL groups (P > 0.05).
The avidity of only IgM TF-specific Abs was significantly higher in cancer compared to both controls (P = 0.002 and P < 0.0001 for donors and the benign group, resp ., suggesting that the anti-TF IgM is the main target for changes in the TF-specific Ab avidity found in cancer patients.
However, the ability of IL-1α to induce serum LF-specific IgG2c and lethal toxin-neutralizing Abs was significantly impaired in CD11c-Myd88 mice when compared with WT mice (p < 0.05).
M-1 and M-23 AQP4-IgG are are significantly associated with a higher number of relapses and longer disease duration.
Production of anti-dsDNA Abs was significantly lower in TgH mice than those of WT and TgL mice (fig 3B).
